The Top 5 News and Updates in Mantle Cell Lymphoma That Patients May Have Missed in 2020

There have been several updates in the field of mantle cell lymphoma (MCL) in 2020. Here, CURE® looks back at some of the top news and updates in this field that patients read the most.

• Data from an analysis of approximately 1,200 patients with MCL collected across 12 treatment centers demonstrated that maintenance Rituxan (rituximab) was associated with improved progression-free survival and overall survival, but an autologous stem cell transplant was not. READ MORE.
• In an interview, an expert from the John Theurer Cancer Center explained how a recent research boom in the treatment of MCL has improved outcomes. READ MORE.
• Velcade (bortezomib) not only delays the progression of MCL when given after stem cell transplant, but also prolongs survival. However, the treatment comes with significant side effects. READ MORE.
• Patients with MCL who were eligible for stem cell transplant saw a 97% overall response rate to a three-drug regimen, according to findings from two clinical trials. READ MORE.
• A treatment regimen with Gazyva (obinutuzumab) plus dexamethasone, high dose cytarabine and cisplatin was well tolerated in patients with MCL who were eligible for bone marrow transplantation, according to study results published in Lancet Haematology. READ MORE.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.